Recently, it has been found that transforming growth factor-β (TGF-β) affects the effects of tumor immunotherapy, and targeted treatment with TGF-β can effectively improve the survival time of patients and reduce side effects (Batlle and Massagué, 2019). Here, TGFB1 is linked to neoplasm.